



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostics.com

Date: February 16, 2026

To,
The Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN

ISIN: INE0B2N01016

Subject: Submission of Earnings Release for the Quarter and Nine Months ended December 31, 2025

Dear Sir/Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to submit herewith a Press Release announcing its strong financial performance for the **third Quarter ended on 31st December, 2025**

The same shall also be made available on the Company's website at www.chandandiagnostics.com.

You are requested to take the above information on record.

Yours faithfully,

For Chandan Healthcare Limited

Rajeev Kumar Nain

Company Secretary & Compliance Officer

Encloses: As above



Chandan Healthcare Records Robust 9M FY26 Performance with ₹203 Cr Total Income; EBITDA Jumps 39%

Lucknow, India – 16th February, 2026 Chandan Healthcare Limited (NSE - CHANDAN), – Chandan Healthcare Limited, one of the leading players in North India's Diagnostics sector, has announced its Unaudited Financial Results for Q3 FY26 & 9M FY26.

Consolidated Key Financial Highlights:

Particulars (₹ Cr)	Q3 FY26	Q3 Y25	YoY	9M FY26	9M FY25	YoY
Total Income	65.77	54.82	↑ 19.99%	203.27	167.99	↑ 21.00%
EBITDA	12.61	9.06	↑ 39.08%	42.59	30.73	↑ 38.58%
EBITDA Margin (%)	19.17%	16.54%	↑ 263 Bps	20.95%	18.30%	↑ 266 Bps
PAT	4.54	4.20	↑ 7.97%	20.14	16.15	↑ 24.71%
PAT Margin (%)	6.90%	7.67%	(77 Bps)	9.91%	9.61%	↑ 29 Bps

For more details, visit the company's website: <https://chandandiagnostics.com/>

Note: During the period, consequent to the implementation of the New Labour Codes and the revision in the wage definition, the Group remeasured its defined benefit obligations in accordance with Accounting Standard (AS) 15-Employee Benefits. The resultant impact attributable to past service has been recognised as past service cost and presented as an Exceptional Item. The Consolidated financial results for the period reflect a loss of 2.23 Cr

Commenting on the financial performance, Mr. Amar Singh, Promoter and Managing Director of Chandan Healthcare Limited, said, "We delivered a steady performance in Q3 FY26 with Total Income of ₹65.77 Cr and EBITDA of ₹12.61 Cr, reflecting healthy operating momentum and improved efficiencies. Our continued focus on network expansion, value-added testing, and operational discipline supported stable margins and consistent growth during the quarter.

During the quarter, we entered into an exclusive five-year partnership with Jeena Sikho Lifecare to provide comprehensive diagnostic services across its existing and upcoming hospitals and centres. This strategic collaboration is expected to generate meaningful recurring revenues at healthy margins over the coming years. We have already commenced the operational rollout under this partnership by setting up diagnostic facilities, and this will progressively ramp up going forward. In addition, we secured a key B2G contract during the quarter, adding business stability and ensuring steady test volumes.

We are expanding rapidly and targeting the development of around 100 labs across 17 states along with over 1,000 franchise collection points over the next three years. With a planned investment of approximately ₹100 Cr to support expansion and advanced testing capabilities including molecular diagnostics, we remain confident of strengthening our pan-India presence and driving sustainable long-term growth."

Key Q3 FY26 Operational Highlights

Strategic Fundraise to Accelerate Expansion	<ul style="list-style-type: none"> • Raised ~₹104 Cr via preferential issue of 44,50,000 fully convertible warrants at ₹234 per warrant. • Participation from promoter group and strategic investors including Jeena Sikho Lifecare and NEGEN Undiscovered Value Fund. • Proceeds allocated towards expansion (₹44.50 Cr), acquisitions (₹50 Cr), and general corporate purposes.
Exclusive Partnership with Jeena Sikho Lifecare	<ul style="list-style-type: none"> • Entered into an exclusive diagnostic partnership covering 23 states and 100+ cities. • Comprehensive pathology and radiology services for IPD and OPD. • Rollout already initiated at Dera Bassi, HiiMS Panchkula; scalable model for nationwide expansion.
Delhi – Prashant Vihar Advanced Diagnostic Centre	<ul style="list-style-type: none"> • Launched advanced centre with expanded genomics testing including whole genome sequencing. • Multi-modality radiology: MRI, Cardiac CT, 4D Ultrasound, Digital X-Ray. • Strengthens preventive and precision healthcare capabilities.
Punjab – Long-Term PPP Radiology Project	<ul style="list-style-type: none"> • Secured ₹26 Cr government PPP project across multiple hospitals. • Deployment of 3 Tesla MRI and 128-slice CT technology. • Enhances presence in public healthcare infrastructure.
Bhopal – Full-Service Diagnostic Centre	<ul style="list-style-type: none"> • Commenced operations with integrated radiology and pathology services. • Equipped with MRI, Cardiac CT, 4D Ultrasound, and Digital X-Ray. • Expands footprint in Central India and strengthens regional network.

About Chandan Healthcare Limited

Chandan HealthCare Limited, established in 2003, is a leading North India-based diagnostics company and a part of the Chandan Group. The company has a strong presence across Uttar Pradesh, Uttarakhand, Rajasthan, and Bihar, Madhya Pradesh and Delhi. It offers comprehensive pathology, radiology, and diagnostic services under one roof, operating 60+ diagnostic centres and over 360 collection centres. Chandan's customer-centric, company-owned model builds trust and ensures quality. Its pharmacy division, Chandan Pharmacy Limited, complements its integrated healthcare offerings.

Key Strengths & Achievements

- **One-Stop Diagnostics:** Delivers over 3,500 pathology and radiology tests through 10 NABL-accredited labs and 5 NABH MIS-accredited centres, supported by 1,600 skilled professionals.
- **Consistent Quality:** Ensures high standards via a company-operated model, backed by experienced leadership and a loyal workforce.
- **Diversified Revenue Streams:** Serves B2C and B2B markets, including individual diagnostics, hospital partnerships, and government contracts, alongside a growing pharmacy division.
- **Cost-Efficient Operations:** Uses refurbished high-end machines to optimise costs while maintaining test accuracy.
- **Customer Loyalty:** Drives repeat business through localised pricing, personalised care, and a strong presence in underserved Tier 2/3 markets.
- **Robust Financials:** In FY25, achieved ₹230.12 Cr in revenue, ₹43.38 Cr in EBITDA, and ₹22.17 Cr in profit, reflecting strong growth and operational efficiency.

Scale & Growth Trajectory

- **Expanding Footprint:** Operates across Uttar Pradesh, Uttarakhand, Rajasthan, Bihar, Madhya Pradesh, and Delhi, with upcoming centres planned in Chhattisgarh, Western Uttar Pradesh and other states.
- **Chandan Medical Centres (CMCs):** Innovative local hubs offering collection, pharmacy, and teleconsultation services to penetrate new markets.
- **Strategic Growth:** Expanding in Western UP and other states through selective franchising for pathology services, while enhancing digital platforms and direct-to-consumer channels to drive scalable growth.


Chandan HealthCare is a trusted leader in diagnostics, blending a strong presence in North India with disciplined expansion and customer-focused innovation. With robust financials and a clear growth strategy, it is well-positioned to deliver value to investors and transform healthcare across emerging and metro markets.


The company was listed on NSE Emerge on 17th February 2025.

Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For Further Information Please Contact Corporate Communication Advisor

	Kirin Advisors Private Limited Sunil Mudgal - Director sunil@kirinadvisors.com
---	--



	<p>+91 98692 75849</p>
--	------------------------

www.kirinadvisors.com

